|Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics ...|
It employs adenosine triphosphate to actively pump cytotoxic drugs out of the cells and is responsible for the efflux of chemotherapeutic drugs such as vinblastine, doxorubicin (Dox) and paclitaxel that leads to a decreased accumulation of drug in ...
Nature.com - Thu, 30 Oct 2014 04:15
|European Medicines Agency Validates the Marketing Authorization Application ...|
... Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type.
PipelineReview.com (press release) - Mon, 29 Sep 2014 05:11
|Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo ...|
Businessweek - Fri, 26 Sep 2014 15:59
|Bristol-Myers Squibb reports positive phase III data for Opdivo in advanced ...|
Pharmaceutical Business Review - Tue, 30 Sep 2014 06:56
|AbbVie Presents Results from Multiple Studies of Investigational Compound ...|
"There is an urgent need to develop novel treatment options for patients with squamous cell carcinoma," said Suresh S. Ramalingam, M.D., director, Division of Medical Oncology, Emory University. "These data demonstrate activity for veliparib in non ...
CNNMoney - Sat, 27 Sep 2014 03:41
|Lung cancer leads all cancer deaths|
Small cell lung cancer that occurs almost exclusively in heavy smokers and is less common than non-small cell lung cancer. • Non-small cell lung cancer is an umbrella for several types of lung cancers that behave in a similar way. Non-small cell lung ...
St. George Daily Spectrum - Mon, 20 Oct 2014 17:44
|An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is ...|
... The study population was homogenous and contained EC patients treated by surgery only. We correlated our results to clinic-pathological parameters, the presence of disseminated tumor cells (DTC) in bone marrow as an indicator of early haematogenous ...
Nature.com - Thu, 30 Oct 2014 00:14
|Agenus' (AGEN) CEO Garo Armen on Q3 2014 Results - Earnings Call ...|
During these nine months of 2014, the Company recorded other non-cash income of $10.8 million related primarily to the impact of the termination of GSK's Phase III MAGE-A3 trial in non-small lung cancer. As previously reported, during the first quarter ...
Seeking Alpha (registration) - Fri, 31 Oct 2014 12:18
|Aristolochic Acid Exposure Linked To High Kidney Cancer Rates In Europe|
The acid has been previously implicated in the development of a kidney disease known as Balkan endemic nephropathy, in small communities along the Danube. In this study, the researchers assessed the correlation between clear-cell renal cell carcinoma ...
Medical Daily - Wed, 29 Oct 2014 11:38
|Jump in skin cancer keeps Manteca dermatologist busy|
Dr. Prescott said he caught the tail end of Vietnam when many of the refugees were housed at the small Crissy Field next to Letterman Army Hospital near the bay where he served his internship as a medical doctor with the rank of Captain. He said by the ...
Manteca Bulletin - Wed, 29 Oct 2014 00:30